title: Waldenström macroglobulinaemia: the key questions.
abstract: In this review, the key issues that pertain to Waldenström disease are discussed in a concise question-and-answer format. Diagnosis, prognosis, and indications for state-of-the-art therapy are updated. Current therapies presented at the 7th International Workshop for Waldenström Macroglobulinaemia are included.
authors: Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
authors: Anita
authors: A
authors: D'Souza
authors: Stephen
authors: S
authors: Ansell
authors: Craig
authors: C
authors: Reeder
authors: Morie A
authors: MA
authors: Gertz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D011379:Prognosis; D012307:Risk Factors; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents
keywords: IgM monoclonal proteins; Waldenström macroglobulinaemia; hyperviscosity; lymphoplasmacytic lymphoma; stem cell transplant